Stryker stroke treatment wows in TREVO 2 trial; LabCorp and XDx to develop diagnostic for lupus flares;

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

 @FierceMedDev: HeartWare gained expanded European approval for its HVAD implant. Trials continue in the U.S., however. Story | Follow @FierceMedDev

> Stryker's ($SYK) Trevo Retriever system to treat acute strokes generated "significantly better" post-device revascularization than a predecessor device, based on results from the company's TREVO 2 clinical trial. Release

> LabCorp ($LH) is joining forces with XDx to develop a diagnostic for lupus flares, or when the autoimmune disease acts up. Story

> Many pregnant women aren't being screened for chlamydia and gonorrhea, as per CDC recommendations, according to a new study by Quest Diagnostics ($DGX) and Rutgers University. Release

> SPR Therapeutics, a neurostimulation pain-relief device company, nailed down a $900,000 loan from the state of Ohio to help the company ramp up production of its signature product. Story

> The Michigan Medical Device Accelerator program won a $400,000 grant from the W.K. Kellogg Foundation. Plans call for using the money to fuel continue fueling more device company startups. Story

> Aerocrine in Sweden gained regulatory approval to market its Niox Mino airway inflammation monitor and test kit in Australia. Both products are meant for asthma patients. Release

Pharma News

 @FiercePharma: Another German drugmaker in takeover talks: Riemser may pick shortlist by next week--BloombergStory | Follow @FiercePharma

> New Teva chief slashes sales forecast by $1B. News

> EU antitrust officials probe parallel trade. Article

> Securities watchdogs reportedly probe Shanghai Pharma deals. Item

> FDA panel draws blood in Xarelto's bid for new use. Report

Biotech News

 @FierceBiotech: Vitamin D boosts TB shot as cancer therapy. More | Follow @FierceBiotech

 @RyanMFierce: Pfizer brings Lipitor brand to mobile app stores. Report | Follow @RyanMFierce

 @JohnCFierce: So Globe's verastem coverage says best-case scenario is start trials in a year, products available in four. A three-year cancer stem cell program? Ha. | Follow @JohnCFierce

> J&J loses key FDA panel vote on Xarelto. Item

> European pharmas join forces on $285M antibiotics collaboration. News

> Sanofi chief highlights high hopes for liver cancer drug. Story

> Upstart biotech lures Vertex founder out of retirement. Report

Pharma Manufacturing News

 @EricPFierce: FDA to Crescendo: We told you so. Marshals seize steroid gel from California firm that was selling unapproved drug. Report | Follow @EricPFierce

> FDA may impose more QA checks on heparin makers. Story

> Recipharm snags $114 million loan, says its shopping. Article

> Heart attack test alert from Alere. More

> FDA takes aim at Spanish drugmaker. Item

CRO News

 @NesaNFierce: What should a CDMO do with 90 million Euros? Buy more CDMOs, as Recipharm announced it will do. Article | Follow @NesaNFierce

> SGS picks up testing company Vitrology for an undisclosed fee. News

> Pfizer's David Simmons joins PPD as new CEO and chairman. Story

> PRA expands European ops with new Dutch and British offices. More

> Quintiles survey shows U.S. and U.K. payers want to improve R&D with increased involvement. Item

Vaccines News

> Wishing you a happy HIV Vaccine Awareness Day. Report

> Vitamin D boosts TB shot as cancer therapy. Article

> DNA vaccine swats TB and HIV. News

> HIV vaccine carries its own adjuvant into clinical trials. Story

And Finally... Dynasil Corporation of America ($DYSL) and the Mayo Clinic will jointly develop therapeutic hypothermia core cooling technology that would protect the brain during cardiac arrest and traumatic brain injury. Release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.